aci-35.030
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT04445831)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauImmunity, active
MAPT immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06544616 | Phase 2 | Jul 22, 2024 | Janssen Pharmaceutica NV |
| NCT04445831 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | AC Immune SA, Janssen Pharmaceutica NV, Johnson and Johnson, University of Amsterdam |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 1 | 1 | 2019 |
| AC Immune SA | For profit | 1 | 1 | 1 | 2019 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2019 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1